Jiangsu, China

Xing Sun


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xing Sun

Introduction

Xing Sun is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in cancer treatment. With a total of three patents to his name, his work has garnered attention in the scientific community.

Latest Patents

Xing Sun's latest patents focus on the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of drugs for treating cancers. This innovative approach aims to enhance the efficacy of cancer therapies by targeting multiple pathways involved in tumor growth and immune evasion. The details of this patent highlight the potential for improved treatment options for patients suffering from various types of cancer.

Career Highlights

Throughout his career, Xing Sun has worked with notable companies in the biopharmaceutical sector. He has been associated with Suzhou Suncadia Biopharmaceuticals Co., Ltd. and Jiangsu Hengrui Medicine Company Ltd. His experience in these organizations has allowed him to contribute to the development of cutting-edge therapies and advancements in medical science.

Collaborations

Xing Sun has collaborated with esteemed colleagues, including Guoqing Cao and Changyong Yang. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the field.

Conclusion

Xing Sun's innovative contributions to cancer treatment through his patents and collaborations underscore his importance in the biopharmaceutical industry. His work continues to pave the way for advancements in medical therapies that can significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…